MOH
- Marketing authorisation holder: ASCENDIS PHARMA BONE
- Status: likely_approved
Yorvipath (PALOPEGTERIPARATIDE) regulatory status in United Arab Emirates.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
ASCENDIS PHARMA BONE holds the UAE marketing authorisation.